First-line treatment for hypertension in autosomal dominant polycystic kidney disease (ADPKD) is what?

First-line treatment for hypertension in autosomal dominant polycystic kidney disease (ADPKD) is what?

• A. Angiotensin receptor blockers
• B. ACE inhibitors
• C. Calcium channel blockers
• D. Thiazide diuretics

Answer: (B)

In ADPKD, high blood pressure is largely driven by activation of the renin-angiotensin system from kidney ischemia due to cyst growth. Blocking this system directly targets the underlying contributor to both hypertension and kidney protection. An ACE inhibitor does this by preventing formation of angiotensin II, leading to dilation of the efferent arteriole, reduced intraglomerular pressure, and less proteinuria, while also lowering blood pressure. This combination provides renal protection and helps slow disease progression, making ACE inhibitors the best first-line choice. ARBs are a good alternative if ACE inhibitors aren’t tolerated, but they are not typically the first choice. Calcium channel blockers and thiazide diuretics can be used as add-ons if needed for additional BP control, but they don’t specifically address the RAAS-mediated renal protection as effectively.

In ADPKD, high blood pressure is largely driven by activation of the renin-angiotensin system from kidney ischemia due to cyst growth. Blocking this system directly targets the underlying contributor to both hypertension and kidney protection. An ACE inhibitor does this by preventing formation of angiotensin II, leading to dilation of the efferent arteriole, reduced intraglomerular pressure, and less proteinuria, while also lowering blood pressure. This combination provides renal protection and helps slow disease progression, making ACE inhibitors the best first-line choice. ARBs are a good alternative if ACE inhibitors aren’t tolerated, but they are not typically the first choice. Calcium channel blockers and thiazide diuretics can be used as add-ons if needed for additional BP control, but they don’t specifically address the RAAS-mediated renal protection as effectively.